Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Simultaneous CMV and Listeria infection following alemtuzumab treatment for multiple sclerosis.

Pappolla A, Midaglia L, Boix Rodríguez CP, Puig AA, Lung M, Camps IR, Castilló J, Mulero P, Vidal-Jordana A, Arrambide G, Rodriguez-Acevedo B, Sastre-Garriga J, Río J, Comabella M, Galán I, Tintoré M, Montalbán X.

Neurology. 2019 Feb 5;92(6):296-298. doi: 10.1212/WNL.0000000000006801. Epub 2018 Dec 26. No abstract available.

PMID:
30587519
2.

Circulating EZH2-positive T cells are decreased in multiple sclerosis patients.

Malhotra S, Villar LM, Costa C, Midaglia L, Cubedo M, Medina S, Fissolo N, Río J, Castilló J, Álvarez-Cermeño JC, Sánchez A, Montalban X, Comabella M.

J Neuroinflammation. 2018 Oct 26;15(1):296. doi: 10.1186/s12974-018-1336-9.

3.

Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course.

Gil-Varea E, Urcelay E, Vilariño-Güell C, Costa C, Midaglia L, Matesanz F, Rodríguez-Antigüedad A, Oksenberg J, Espino-Paisan L, Dessa Sadovnick A, Saiz A, Villar LM, García-Merino JA, Ramió-Torrentà L, Triviño JC, Quintana E, Robles R, Sánchez-López A, Arroyo R, Alvarez-Cermeño JC, Vidal-Jordana A, Malhotra S, Fissolo N, Montalban X, Comabella M.

J Neuroinflammation. 2018 Sep 14;15(1):265. doi: 10.1186/s12974-018-1307-1.

4.

Myasthenia gravis following alemtuzumab therapy for multiple sclerosis.

Midaglia L, Gratacòs M, Caronna E, Raguer N, Sastre-Garriga J, Montalban X, Tintoré M.

Neurology. 2018 Sep 25;91(13):622-624. doi: 10.1212/WNL.0000000000006251. Epub 2018 Aug 24. No abstract available.

PMID:
30143565
5.

Ocrelizumab: a new milestone in multiple sclerosis therapy.

Mulero P, Midaglia L, Montalban X.

Ther Adv Neurol Disord. 2018 May 10;11:1756286418773025. doi: 10.1177/1756286418773025. eCollection 2018. Review.

6.

The value of oligoclonal bands in the multiple sclerosis diagnostic criteria.

Arrambide G, Tintore M, Espejo C, Auger C, Castillo M, Río J, Castilló J, Vidal-Jordana A, Galán I, Nos C, Mitjana R, Mulero P, de Barros A, Rodríguez-Acevedo B, Midaglia L, Sastre-Garriga J, Rovira A, Comabella M, Montalban X.

Brain. 2018 Apr 1;141(4):1075-1084. doi: 10.1093/brain/awy006.

PMID:
29462277
7.

Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome.

Matute-Blanch C, Villar LM, Álvarez-Cermeño JC, Rejdak K, Evdoshenko E, Makshakov G, Nazarov V, Lapin S, Midaglia L, Vidal-Jordana A, Drulovic J, García-Merino A, Sánchez-López AJ, Havrdova E, Saiz A, Llufriu S, Alvarez-Lafuente R, Schroeder I, Zettl UK, Galimberti D, Ramió-Torrentà L, Robles R, Quintana E, Hegen H, Deisenhammer F, Río J, Tintoré M, Sánchez A, Montalban X, Comabella M.

Brain. 2018 Apr 1;141(4):1085-1093. doi: 10.1093/brain/awy021.

PMID:
29452342
8.

[Rituximab: its efficacy, effectiveness and safety in the treatment of multiple sclerosis].

Midaglia L, Mora L, Mulero P, Sastre-Garriga J, Montalban X.

Rev Neurol. 2018 Jan 1;66(1):25-32. Review. Spanish.

9.

NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients.

Malhotra S, Sorosina M, Río J, Peroni S, Midaglia L, Villar LM, Álvarez-Cermeño JC, Schroeder I, Esposito F, Clarelli F, Zettl UK, Lechner-Scott J, Spataro N, Navarro A, Comi G, Montalban X, Martinelli-Boneschi F, Comabella M.

Mult Scler. 2018 Oct;24(11):1507-1510. doi: 10.1177/1352458517739137. Epub 2017 Nov 9.

10.

Lesion topographies in multiple sclerosis diagnosis: A reappraisal.

Arrambide G, Tintore M, Auger C, Río J, Castilló J, Vidal-Jordana A, Galán I, Nos C, Comabella M, Mitjana R, Mulero P, de Barros A, Rodríguez-Acevedo B, Midaglia L, Sastre-Garriga J, Rovira A, Montalban X.

Neurology. 2017 Dec 5;89(23):2351-2356. doi: 10.1212/WNL.0000000000004715. Epub 2017 Nov 3.

11.

Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor.

Arrambide G, Rovira A, Sastre-Garriga J, Tur C, Castilló J, Río J, Vidal-Jordana A, Galán I, Rodríguez-Acevedo B, Midaglia L, Nos C, Mulero P, Arévalo MJ, Comabella M, Huerga E, Auger C, Montalban X, Tintore M.

Mult Scler. 2018 Mar;24(3):301-312. doi: 10.1177/1352458517697830. Epub 2017 Mar 16.

PMID:
28301287
12.

Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.

Matute-Blanch C, Río J, Villar LM, Midaglia L, Malhotra S, Álvarez-Cermeño JC, Vidal-Jordana A, Montalban X, Comabella M.

J Neuroimmunol. 2017 Feb 15;303:62-65. doi: 10.1016/j.jneuroim.2016.12.006. Epub 2016 Dec 18.

PMID:
28063616
13.

Experience with fampridine in clinical practice: analysis of a possible marker of clinical response.

Alvarez-Payero M, Valeiras-Muñoz C, Lion-Vázquez S, Piñeiro-Corrales G, Muñoz-García D, Midaglia L.

Int J Neurosci. 2017 Oct;127(10):915-922. doi: 10.1080/00207454.2017.1279614. Epub 2017 Mar 30.

PMID:
28054826
14.

[Fingolimod: effectiveness and safety in routine clinical practice. An observational, retrospective, multi-centre study in Galicia].

Pato-Pato A, Midaglia L, Costa-Arpin E, Rodriguez-Regal A, Puy-Nunez A, Rodriguez-Rodriguez M, Lopez-Real A, Llaneza-Gonzalez MA, Garcia-Estevez DA, Moreno-Carretero MJ, Escriche-Jaime D, Aguado-Valcarcel ML, Munoz D, Prieto JM, Lorenzo-Gonzalez JR, Amigo-Jorrin MC.

Rev Neurol. 2016 Sep 5;63(s01):S13-S18. Spanish.

PMID:
27658431
15.

Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis.

Tintore M, Otero-Romero S, Río J, Arrambide G, Pujal B, Tur C, Galán I, Comabella M, Nos C, Arévalo MJ, Vidal-Jordana A, Castilló J, Rodríguez-Acevedo B, Midaglia L, Mitjana R, Auger C, Sastre-Garriga J, Rovira À, Montalban X.

Neurology. 2016 Sep 27;87(13):1368-74. doi: 10.1212/WNL.0000000000003144. Epub 2016 Aug 26.

PMID:
27566747
16.

Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes.

Sepúlveda M, Armangue T, Martinez-Hernandez E, Arrambide G, Sola-Valls N, Sabater L, Téllez N, Midaglia L, Ariño H, Peschl P, Reindl M, Rovira A, Montalban X, Blanco Y, Dalmau J, Graus F, Saiz A.

J Neurol. 2016 Jul;263(7):1349-60. doi: 10.1007/s00415-016-8147-7. Epub 2016 May 4.

17.

Clinical response and tolerability of fampridine in clinical practice.

Costa-Arpín E, Pato A, Rodríguez-Regal A, Midaglia L, Yáñez R, Muñoz D, Lorenzo JR, Amigo C, Prieto JM.

Neurodegener Dis Manag. 2016 Apr;6(2):99-105. doi: 10.2217/nmt-2015-0004. Epub 2016 Apr 1.

PMID:
27032814
18.

An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy.

Midaglia L, Juega Mariño JM, Sastre-Garriga J, Rovira A, Vidal-Jordana A, López-Pérez MA, Marzo-Sola ME, Librada Escribano F, Montalban X.

Mult Scler. 2016 May;22(6):842-6. doi: 10.1177/1352458516638557. Epub 2016 Mar 18.

PMID:
26993120
19.

Associated Inosine to interferon: results of a clinical trial in multiple sclerosis.

Muñoz García D, Midaglia L, Martinez Vilela J, Marín Sánchez M, López González FJ, Arias Gómez M, Dapena Bolaño D, Iglesias Castañón A, Alonso Alonso M, Romero López J.

Acta Neurol Scand. 2015 Jun;131(6):405-10. doi: 10.1111/ane.12333. Epub 2014 Oct 14.

PMID:
25313094
20.

[Tropical spastic paraparesis: a report of a new case in Spain].

Midaglia L, Pato-Pato A, Rodriguez-Constenla I, Santos-Armentia E, Cimas-Hernando I, Lopez-Fernandez M, Munoz-Garcia D, Valeiras-Munoz C, Lorenzo-Gonzalez JR.

Rev Neurol. 2014 Jun 16;58(12):573-5. Review. Spanish.

21.

Severe haematological complications during treatment with natalizumab.

Midaglia L, Rodriguez Ruiz M, Muñoz-García D.

Mult Scler. 2012 Nov;18(11):1644-6. doi: 10.1177/1352458512442262. Epub 2012 Mar 21.

PMID:
22438058
22.

[Skin infection due to Mycobacterium marinum in a patient being treated with natalizumab].

Midaglia L, Munoz-Garcia D, Sopena B, Rodriguez-Cerdeira C.

Rev Neurol. 2011 Jun 1;52(11):701-2. Spanish. No abstract available.

Supplemental Content

Loading ...
Support Center